On October 14,Li Daning, Deputy Director of StateAdministration of Traditional Chinese Medicine, Lu Jianwei and Zhang Jianfeng, Division Chiefs of Science and Technology Division of StateAdministration of Traditional Chinese Medicine, and Professor Ye Zuguang, researcher of China Academy of Chinese Medical Sciences and Ex-director of Chinese Medicine Office of SFDA Evaluation Center came to YRPG for survey.
The delegation of Li Daning visited the oral liquid workshop and freeze-dried powder workshop, learn more about the workshop production facilities and processes, and spoke highly of the practice that the enterprise adheres to ensuring quality and seeking development through scientific and technical innovation.
Li Daning also listened to the special topic about how YRPG cooperated with SUB of the Netherlands to expand the EU market. YRPG has planned to establish a platform in the Netherlands for TCM registration, TCM quality standard research, and Chinese metabolomics research. Via the to-be-built marketing network in the Netherlands and based on the mutual recognition regime among the EU member states, YRPG expects to open the channel for TCM products in the European market. On this meeting, leaders and experts offer advice and suggestions on the YRPG-SUB cooperation and the choice of TCM products to export.
Xu Jingren introduced the TCM general plan in YRPG's future development plan. He said, during the "12th Five Year Plan", YRPG had planned to invest 2 to 3 billion to build TCM high-tech industrial park and develop a group of Chinesepatentmedicines, herbal medicines and health care products. This makes its TCM industry scale be leading in China.
Li Daning gave his recognition to YRPG's TCM development plan and expressed his expectation. That is, YRPG may preferentially develop the projects that are in accordance with the planned projects in "12th Five Year Plan", adhere to scientific and technical innovation as the driving force, make TCM and health care industries bigger and stronger, and expand international market to play a pioneer role in prospering national medicine industry.
Zhang Baohua, general manager of YRPG's Jiang Su Pharmaceutical Co. Ltd, and Zheng Lu, Deputy Director of Chinese Medicine Research Institute of Pharmaceutical Research, attended the meeting.